HKU Scholars Hub: Browsing DSpace

Browsing by Author Kang, YK

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 11 of 11

	Title	Author(s)	Issue Date	Views
	Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial Journal:JAMA	Zhu, AX Kudo, M Assenat, E Cattan, S Kang, YK Lim, HY Poon, RTP	2014	40
	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial Journal:JAMA Oncology	Yau, TCC Kang, YK Kim, TY El-Khoueiry, AB Santoro, A Sangro, B Melero, I Kudo, M Hou, MM Matilla, A Tovoli, F Knox, JJ He, AR El-Rayes, BF Acosta-Rivera, M Lim, HY Neely, J Shen, Y Wisniewski, T Anderson, J Hsu, C	2020	70
	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma Journal:Journal of Hepatology	Zhu, AX Chen, D He, W Kanai, M Voi, M Chen, LT Daniele, B Furuse, J Kang, YK Poon, RTP Vogel, A Chiang, DY	2016	61
	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012 Journal:Lancet Oncology	Ku, G Tan, IB Yau, TCC Boku, N Laohavinij, S Cheng, AL Kang, YK de Lima Lopes, G	2012	56
	Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis From the CheckMate 040 Study Journal:Journal of Hepatology	Yau, TCC Hsu, C Kim, TY Choo, S Kang, YK Hou, MM Numata, K Yeo, W Chopra, A Ikeda, M Kuromatsu, R Moriguchi, M	2019	272
	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Journal:Lancet	El-Khoueiry, AB Sangro, B Yau, TCC Crocenzi, TS Kudo, M Hsu, C Kim, TY Choo, SP Trojan, J Welling, TH Meyer, T Kang, YK Yeo, W Chopra, A Anderson, J Dela Cruz, C Lang, L Neely, J Tang, H Dastani, HB Melero, I	2017	172
	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma Journal:Journal of Hepatology	Finn, RS Poon, RTP Yau, TCC Klümpen, HJ Chen, LT Kang, YK Kim, TY Gomez-Martin, C Rodriguez-Lope, C Kunz, T Paquet, T Brandt, U Sellami, D Bruix, J	2013	70
	Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma Journal:Annals of Oncology	Kang, YK Yau, TCC Park, JW Lim, HY Lee, TY Obi, S Chan, SL Qin, S Kim, RD Casey, M Chen, C Bhattacharyya, H Williams, JA Valota, O Chakrabarti, D Kudo, M	2015	68
	Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma Journal:Hepatology	Cheng, AL Thongprasert, S Lim, HY Sukeepaisarnjaroen, W Yang, TS Wu, CC Chao, Y Chan, SL Kudo, M Ikeda, M Kang, YK Pan, H Numata, K Han, G Balsara, B Zhang, Y Rodriguez, AM Zhang, Y Wang, Y Poon, RTP	2016	94
	Safety and Antitumor Activity of Nivolumab (Nivo) in Patients (pts) with Advanced Hepatocellular Carcinoma (HCC): Interim Analysis of Dose-Expansion Cohorts from the Phase 1/2 CheckMate-040 Study Proceeding/Conference:Liver Cancer	Sangro, B Melero, I Yau, TCC Hsu, C Kudo, M Crocenzi, TS Kim, TY Choo, SP Trojan, J Meyer, T Kang, YK Anderson, J dela Cruz, C Lang, L Neely, J El-Khoueiry, AB	2016	192
	Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study Journal:Journal of Clinical Oncology	Kelley, RK Sangro, B Harris, W Ikeda, M Okusaka, T Kang, YK Qin, S Tai, DWM Lim, HY Yau, T Yong, WP Cheng, AL Gasbarrini, A Damian, S Bruix, J Borad, M Bendell, J Kim, TY Standifer, N He, P Makowsky, M Negro, A Kudo, M Abou-Alfa, GK	2021	23

Showing results 1 to 11 of 11